Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 1 sale; 157 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $195.1M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $13.5K in total
- 1
- 13F holdersQ2 2026, +1 vs. previous quarter
- 157
- 13F valueReported value at the end of Q2 2026
- $193.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $6.65M
- −51.2% year over year
- Net income, FY2025
- -$136.3M
- No comparable prior period
- Free cash flow, FY2025
- -$112.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- −100.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $136.3M (2051.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 9.97M
- Shares sold short
- Change
- −645.6K
- −6.1% vs. previous
- Days to cover
- 8.32
- At average daily volume
Superinvestors holding FATE, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding FATE at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Fate Therapeutics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)4:01 PM ET | Nov 3 | 1 day | Adawi KamalChief Financial Officer | SSale | −6.58K | $2.05 | −$13.5K | −6.6%93.4K after | |
| Aug 5, 2026 (view filing)4:03 PM ET | Aug 4 | 1 day | Tahl CindySee Remarks | SSale | −38.8K | $2.46 | −$95.4K | −6.2%589.4K after | |
| Aug 5, 2026 (view filing)4:01 PM ET | Aug 4 | 1 day | Valamehr BahramPresident and CEO | SSale | −43.9K | $2.46 | −$108.1K | −6.9%591.8K after | |
| May 21, 2026 (view filing) | May 20 | 1 day | Tahl CindySee Remarks | SSale | −25.6K | $1.88 | −$48.1K | −3.9%628.2K after | |
| May 21, 2026 (view filing) | May 20 | 1 day | Valamehr BahramPresident and CEO | SSale | −28.9K | $1.88 | −$54.4K | −4.4%635.8K after | |
| Jan 12, 2026 (view filing) | Jan 9 | 3 days | Tahl CindySee Remarks | SSale | −10.6K | $1.06 | −$11.2K | −2.7%387.1K after | |
| Jan 12, 2026 (view filing) | Jan 9 | 3 days | Valamehr BahramPresident and CEO | SSale | −5.19K | $1.07 | −$5.55K | −1.5%329.7K after | |
| Aug 5, 2025 (view filing) | Aug 4 | 1 day | Tahl CindySee Remarks | SSale | −9.04K | $1.06 | −$9.58K | −2.2%397.7K after | |
| Aug 5, 2025 (view filing) | Aug 4 | 1 day | Valamehr BahramPresident and CEO | SSale | −14.5K | $1.06 | −$15.3K | −4.1%334.9K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Bressi Jerome CharlesSee Remarks | SSale | −5.98K | $1.55 | −$9.27K | −2.2%270.2K after |
Top 10 13F holders, Q2 2026
See all 157 holdersThe largest institutional positions in Fate Therapeutics Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Redmile Group, LLC | 12,872,946 | $34.8M | 2.33% | 00.0% | Unchanged |
| BlackRock, Inc. | 7,298,895 | $19.7M | 0.00% | −2,769,719−27.5% | Reduced |
| Vanguard Portfolio Management LLC | 4,545,893 | $12.3M | 0.00% | +411,308+9.9% | Added |
| Vanguard Capital Management LLC | 4,445,536 | $12.0M | 0.00% | +253,473+6.0% | Added |
| Acadian Asset Management LLC | 4,351,250 | $11.7M | 0.01% | +231,050+5.6% | Added |
| AQR Capital Management LLC | 3,837,229 | $10.4M | 0.00% | +835,708+27.8% | Added |
| Two Sigma Investments, LP | 3,589,863 | $9.69M | 0.01% | +123,077+3.6% | Added |
| Johnson & Johnson | 3,379,064 | $9.12M | 1.14% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 2,983,268 | $8.05M | 0.01% | +8,585+0.3% | Added |
| Millennium Management LLC | 2,433,978 | $6.57M | 0.00% | +2,433,978 | New |
Holders of 5% or more of FATE
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Fate Therapeutics Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Redmile Group, LLC | 13D/A | 14.99%19.2M shares | +0.09 ppfrom 14.90% | Jan 12, 20218 filings | Nov 9, 2026 | SEC |
Politician trades
All politician trades in FATE1 member of Congress reported 1 trade in Fate Therapeutics Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Feb 24, 2023 |  Daniel S. Goldman House · NY | Sell | $1K-$15K |
House · NY · Feb 24, 2023
Sell$1K-$15K